CROs Icon and Covance signed a pair of separate partnerships in the world of cancer diagnostics, each betting that new technologies in oncology testing will increase global demand.
Contract drug developer Aptuit has bolstered its in-house production capabilities and can now churn out doses for Phase III trials, a move the company says was motivated by client demand.
Patient recruitment specialist Synexus has opened up new outposts across Eastern Europe, following through on its promise to expand around the globe after changing hands for $128 million.
CRO Frontage Laboratories has acquired a 45% stake in New Jersey's BDM Consulting, a biometrics-focused company looking to expand the market for its data services.
Chinese CRO giant WuXi PharmaTech is looking to expand its investment portfolio, planning to debut a $250 million new fund that will back startups in the U.S. and China.
Swedish contractor Recipharm has deepened its ties with partner Pharmanest, taking up a 25% stake in the biotech as the two collaborate on a pain drug.
Parexel is expanding its efforts in so-called model-based drug development, using data analytics to flesh out a drug's potential safety, efficacy and interactions before beginning a clinical trial.
Preclinical CRO Charles River Laboratories is paying $212 million in cash to buy a company focused on quality-control testing, expanding its presence in the market for bacterial detection services.
CRO BioClinica inked a deal to acquire MediciGroup, a patient recruitment and retention outfit that uses technology to keep subjects engaged in trials and minimize dropouts.
Quintiles and Quest Diagnostics rolled out Q2 Solutions, a $575 million joint venture that pairs the CRO's experience running studies with the latter company's expertise in lab tests.
GVK BioSciences, an Indian CRO under fire from European regulators, has signed a deal with Australia's Akaal Pharma to help the company move its in-development psoriasis treatment into mid-stage trials.
Covance, now a division of LabCorp, has signed a two-year partnership with the Society for Clinical Research Sites, joining a growing list of CROs working to improve communication between sponsors and investigators.
PPD, angling to stand out among CROs running pediatric trials, has cemented a network of 8 global sites to accelerate the process of starting studies on kids.
CRO BioClinica has opened new outposts in the U.K. and Germany, expanding its European footprint and scaling up its capabilities in medical imaging.
French contract drugmaker Novasep is investing €10 million ($11 million) to build an antibody-drug conjugate facility at its Le Mans outpost.
PRA Health Sciences, a year removed from its $300 million IPO, unveiled an end-to-end technology platform that pools trial design, planning and monitoring in one place, touting its new offering as a major step forward for the CRO.
Icon, at work on new approaches to educating potential study participants, launched a new technology designed to inform patients of the possible risks and benefits of a clinical trial before they meet with a physician.
Huntingdon Life Sciences, a year removed from acquiring Harlan Laboratories, is changing the combined company's name to Envigo as it works to expand its presence on the CRO market.
CRO giant Parexel is planning to shed about 850 jobs over the next year in an effort to cut costs as it lowers its financial expectations for the quarter.
Massachusetts CRO Veristat has cut the ribbon on its new West Coast base, opening a Bay Area operation in an effort to maintain its recent growth.